News

Home > News > SJTU Team Identifying Potential Targets for the Development of Anti-M. tuberculosis (Mtb) Drugs

SJTU Team Identifying Potential Targets for the Development of Anti-M. tuberculosis (Mtb) Drugs

March 28, 2018      Author: Jiang Hewei

On March 27, 2018, the EBioMedicine published an online research paper identifying an Effective Inhibitor Binding Site of M. tuberculosis Ubiquitin-like Protein Ligase PafA Using Purified Proteins and M. smegmatis, done by Tao Shengce team withShanghai Center Systems Biomedicine.  The EBioMedicine, aiming at promoting the transfer from Basic Medicine Study to Clinical Medicine, is an open access journal jointly supported by The Lancet, one of the four most prestigious clinical medicine journals, and Cell, a CNS journal. The research finds that Serine 119 (S119), situated within a critical, small-molecule accessible region of Mtb PafA, is a highly promising and efficient target for the development of inhibitors of M. tuberculosis drugs. 

Tao Shengce, a researcher in Shanghai Center Systems Biomedicine, is the corresponding Author and Doc. Jiang Hewei is the first author for the paper. The main research interest of Tao Shengce is the development of cutting-edge technologies of protein microarray and biochip and mycobacterium tuberculosis systems biology and translational medicine. He has founded a series of technological platforms specialized in technologies of protein microarray and biochip, based on which systematical and intensive researches related to medical research has been conducted. 

The research is sponsored by the Thirteenth Five-year Plan Key Specialized Project for Protein Machine and Life Cycle Monitoring, Twelfth Five-year Plan Infectious Diseases Major Project and the National Natural Science Foundation of China.

 

Translated by Liu Yixuan   Reviewed by Wang Bingyu